- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CSE Bulletin: New Listing - Biomind Labs Inc. (BMND) | 1 | Newsfile | Le 7 août/August 2026
The common shares of Biomind Labs Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the listing date.
Biomind... ► Artikel lesen | |
| Do | Biomind Labs Inc: Biomind Labs to be delisted from Cboe Canada | 1 | Stockwatch | ||
| Do | Biomind Labs Inc.: Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada | 358 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming breakthroughs... ► Artikel lesen | |
| BIOMIND LABS Aktie jetzt für 0€ handeln | |||||
| 03.07. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 02.06. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 21.04. | Biomind Labs Inc: Biomind cheers executive order for psychedelic research | 3 | Stockwatch | ||
| 20.04. | Biomind Labs Inc.: Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States | 397 | ACCESS Newswire | A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20... ► Artikel lesen | |
| 07.03. | Biomind Labs Inc: Biomind Labs under Cboe Canada delisting review | 2 | Stockwatch | ||
| 13.02. | Biomind Labs Inc: Biomind Labs shareholders approve all matters at AGSM | 1 | Stockwatch | ||
| 27.01. | Biomind Labs Inc.: Biomind Labs Announces CAD $2.52 Million Private Placement Financing | 478 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 27.01. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 27.01.2026 | 214 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 27.01.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 27.01.2026ISIN NameDE000HEL0GB7 LB.HESS.THR.CARRARA04S/25XS2576250448... ► Artikel lesen | |
| 03.12.25 | Biomind Labs Inc.: Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood | 400 | ACCESS Newswire | BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 01.12.25 | XFRA 3XI: WIEDERAUFNAHME/RESUMPTION | 281 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 25.11.25 | Biomind Labs Inc.: Biomind Labs Announces Revocation of Cease Trade Order | 520 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has revoked... ► Artikel lesen | |
| 18.11.25 | Biomind Labs Inc.: Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board | 542 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AAP IMPLANTATE | 1,650 | +4,43 % | EQS-HV: aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: aap Implantate AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin... ► Artikel lesen | |
| CLEARMIND MEDICINE | 1,640 | +0,61 % | Clearmind Medicine Inc.: Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study | Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND-100 in patients with Alcohol Use Disorder (AUD) - a key milestone... ► Artikel lesen | |
| QIAGEN | 38,450 | +5,46 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 4,425 | -91,33 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen | |
| COGENT BIOSCIENCES | 41,160 | -2,90 % | Cogent Biosciences reports Q2 results | ||
| APOGEE THERAPEUTICS | 134,63 | -0,16 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,450 | +0,76 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| ARCUTIS BIOTHERAPEUTICS | 25,650 | +1,42 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EVOTEC | 3,656 | +5,54 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 365,09 | +1,20 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| SUMMIT THERAPEUTICS | 14,595 | +4,55 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics | ||
| TANGO THERAPEUTICS | 27,130 | +0,22 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,275 | +1,71 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| CG ONCOLOGY | 75,08 | -0,03 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,100 | -6,33 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen |
Das Unternehmen BIOMIND LABS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,037 Euro und damit -8,75 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMIND LABS INC finden Sie auf Wallstreet Online.